Keywords
Spinal Cord Injury, Anti inflammatory cytokine, Neuroprotector, Experimental, Laminectomy
This article is included in the Cell & Molecular Biology gateway.
Spinal Cord Injury, Anti inflammatory cytokine, Neuroprotector, Experimental, Laminectomy
Spinal cord injury (SCI) is a pathological condition that is known to cause severe neurological deterioration resulting in physical dependency, morbidity, mortality and financial burden for decades.1 Even tough significant research has been conducted to develop effective treatments for SCI, until now none of these treatments has shown any meaningful effect to improve functional outcome after injury.2
Demographic data suggest that SCI mainly affects the male population with over 80% cases occurring in males between 25 to 45 year of age.3 Interestingly, not only do males have a higher incidence rate of SCI, but some studies have also shown males tend to have worse recovery rates compared with females.4 This phenomenon is thought to be caused by female sex hormone such as progesterone and estrogen, that have shown modest neuroprotective behaviour in brain injury.5
In general, pathophysiology of traumatic SCI comprises primary and secondary injury. The primary injury is caused by the initial traumatic event such as compression, distraction, laceration and transection; this kind of injury causes irreversible damage to the spinal cord. In contrast, secondary injury, including processes such as neuroinflammation, spinal cord ischemia, and cellular excitotoxicity which begin soon after the initial trauma, give a window of opportunity to prevent further damage of the spinal cord. Therefore, managing secondary injuries remains the main target for SCI treatment.6,7
Above all the potential threats from secondary SCI, neuroinflammation is thought to be the key component causing many local and systemic consequences. It is known that injury to the spinal cord initiates an inflammatory-mediated response that could alter the repair processes within the nervous system and cause more damage to the nerves. Therefore, managing inflammation is thought to be an important factor for optimizing the outcome of SCI.8
Inflammation response in the spinal cord begins after macrophages activation and recruitment at the site of injury; activation of these macrophages could work in different pathways promoting, but also inhibiting the inflammation. Macrophages initiate inflammation by releasing pro-inflammatory cytokines (IL-1, IL-6, IL-8, IFN-γ and TNF-α) and other chemical mediators. After three or four days, macrophages that initiate and maintain the inflammation will then be deactivated by anti-inflammatory cytokines (IL-4, IL-10, IL-13 and TGF-β) that are also mainly produced by macrophages. The way that macrophages could regulate the inflammatory process is through the activation and counterbalance of pro- and anti-inflammatory cytokines. This balance determines the net effect of the inflammatory response in SCI.9,10
ACTH4-10Pro8-Gly9-Pro10 is an adrenocorticotropic hormone analogue that is known to have an anti-inflammatory effect.11 It has also been used in many conditions such as stroke, traumatic brain injury and Alzheimer disease as a neuroprotective agent with no report of serious complications.12
This experimental study was intended to show the effect of ACTH4-10 administration on anti-inflammatory cytokine levels in the spinal cord after acute SCI.
In this study we used 12-week-old male Sprague Dawley rats weighing 250-300 g to reproduce homogenous sample for SCI models and eliminate confounding factor such as sex hormone. This animal study obtained ethical clearance by the Airlangga University animal care and use committee number 2.KE.094.07.2021 to ensure all effort was taken to reduce animal suffering. After randomization, 27 samples were divided into nine groups of three samples each. Laminectomy at the level of second thoracic vertebra was performed on all the samples. We took one group with the spinal cord left uninjured as a baseline control. The other samples became the treatment groups, in which SCI was performed by compressing the spine using an aneurysm clip in one minute with a clamping force of 20 g to reproduce mild SCI (four groups) and 35 g for severe SCI models (four groups).13 The laminectomy site was then closed with sutures and the Sprague Dawley rats were kept alive.
After closing the suture, all treatment groups were divided into two subgroups. Placebo control groups were given 0.9 % NaCl intranasally, while the positive treatment groups were given ACTH4-10Pro8-Gly9-Pro10 intranasally at a 300 mg/kg dose. Each group was divided again into two groups to be respectively terminated at 3 hours and 6 hours after compression. Myelum transection was performed at the level of injured myelum after the termination.
SCI myelum samples were fixed in 10% formalin and examined for IHC with specific monoclonal antibodies for each of IL-4, IL-10 and IL-13. Examination was done on the posterior horn of myelum to ensure homogenous sampling area in each group. Then anti-inflammatory cytokines were counted per 100 cells using associated anti-monoclonal antibodies and viewed with a light microscope at 1000× magnification. Cells with a brown colour in the cytoplasm showed positive expression of each anti-inflammatory cytokine.
The result of cytokine level measurements in each group are shown in a relative expression graph. Normality data analysis was performed using a Shapiro-Wilk test. Normally distributed data were analyzed with ANOVA while the data with non-normal distribution were analyzed using a Kruskal-Wallis test, followed by a non-parametric Mann-Whitney U test.
We carried out an experimental study in 27 male Sprague Dawley rats weighing 250-300 g, we severed the spinal cords in the area of injury, then we fixed the specimen with formalin. The specimen was then cut into 4-6 μm-thick slices with rotatory microtome and mounted on glass slides before further staining as seen in Figure 1.
After immunohistochemistry staining with each specific antibody we examined the posterior horn area and counted stained cell number per 100 cells with a light microscope at 1000× magnification. Positive cells appeared brown as seen in Figure 2.
Immunoreacted neutrophil cytoplasm that stained brown after using monoclonal antibodies are shown. White arrows mark positive stained neutrophils for IL-4 (A), IL-10 (B) and IL-13 (C) in mild spinal cord injury (SCI) group.
Table 1 shows higher IL-4 levels in both mild and severe SCI models with ACTH4-10Pro8-Gly9-Pro10 administration that were terminated after three and six hours, compared to the placebo group.
Group | IL-4 expression | ||
---|---|---|---|
Mean | Standard deviation | p | |
Control | 5.96 | 2.52 | 0.005* |
Mild SCI NaCl 0.9% 3 hours | 6.29 | 3.40 | |
Mild SCI NaCl 0.9% 6 hours | 5.61 | 2.45 | |
Mild SCI ACTH4-10 3 hours | 10.39 | 1.67 | |
Mild SCI ACTH4-10 6 hours | 8.05 | 1.62 | |
Control | 5.75 | 2.20 | 0.001* |
Severe SCI NaCl 0.9% 3 hours | 7.32 | 2.26 | |
Severe SCI NaCl 0.9% 6 hours | 5.29 | 2.16 | |
Severe SCI ACTH4-10 3 hours | 9.36 | 1.98 | |
Severe SCI ACTH4-10 6 hours | 9.21 | 1.37 |
Table 2 shows higher IL-10 levels in both mild and severe SCI models with ACTH4-10Pro8-Gly9-Pro10 administration and who were terminated after three and six hours compared to the placebo group.
Group | IL-10 expression | ||
---|---|---|---|
Mean | Standard deviation | p | |
Control | 5.57 | 1.573 | <0.001* |
Mild SCI NaCl 0.9% 3 hours | 6.86 | 1.848 | |
Mild SCI NaCl 0.9% 6 hours | 4.71 | 1.741 | |
Mild SCI ACTH4-10 3 hours | 14.64 | 2.893 | |
Mild SCI ACTH4-10 6 hours | 11.46 | 1.350 | |
Control | 5.36 | 1.587 | |
Severe SCI NaCl 0.9% 3 hours | 7.07 | 2.344 | |
Severe SCI NaCl 0.9% 6 hours | 5.71 | 1.629 | |
Severe SCI ACTH4-10 3 hours | 13.25 | 3.086 | |
Severe SCI ACTH4-10 6 hours | 9.54 | 2.138 |
Table 3 shows higher IL-13 levels in both mild and severe SCI models with ACTH4-10Pro8-Gly9-Pro10 administration and who were terminates after three and six hours compared to the placebo group.
Group | IL-13 expression | ||
---|---|---|---|
Mean | Standard deviation | p | |
Control | 3.86 | 1.682 | <0.001* |
Mild SCI NaCl 0.9% 3 hours | 7.86 | 2.445 | |
Mild SCI NaCl 0.9% 6 hours | 6.25 | 2.046 | |
Mild SCI ACTH4-10 3 hours | 13.36 | 1.676 | |
Mild SCI ACTH4-10 6 hours | 11.57 | 3.313 | |
Control | 4.50 | 1.893 | |
Severe SCI NaCl 0.9% 3 hours | 5.79 | 1.410 | |
Severe SCI NaCl 0.9% 6 hours | 5.68 | 1.718 | |
Severe SCI ACTH4-10 3 hours | 10.18 | 3.570 | |
Severe SCI ACTH4-10 6 hours | 9.00 | 1.893 |
Using Shapiro-Wilk test, we found our data had a normal distribution; further statistical analysis was carried out with a post hoc study using the Tukey method (Tables 4-9).
Group | Mean | Standard deviation | Group | Mean | Standard deviation | p |
---|---|---|---|---|---|---|
Control | 5.96 | 2.52 | NaCl 0.9% 3 hours | 6.29 | 3.40 | 0.999 |
NaCl 0.9% 6 hours | 5.61 | 2.45 | 0.999 | |||
ACTH4-10 3 hours | 10.39 | 1.67 | 0.015* | |||
ACTH4-10 6 hours | 8.05 | 1.62 | 0.510 | |||
NaCl 0.9% 3 hour | 6.29 | 3.40 | NaCl 0.9% 6 hours | 5.61 | 2.45 | 0.984 |
ACTH4-10 3 hours | 10.39 | 1.67 | 0.027* | |||
ACTH4-10 6 hours | 8.05 | 1.62 | 0.663 | |||
NaCl 0.9% 6 hour | 5.61 | 2.45 | ACTH4-10 3 hours | 10.39 | 1.67 | 0.007* |
ACTH4-10 6 hours | 8.05 | 1.62 | 0.353 | |||
ACTH4-10 3 hour | 10.39 | 1.67 | ACTH4-10 6 hours | 8.04 | 1.62 | 0.382 |
Group | Mean | Standard deviation | Group | Mean | Standard deviation | p |
---|---|---|---|---|---|---|
Control | 5.57 | 1.573 | NaCl 0.9% 3 hours | 6.86 | 1.848 | 0.734 |
NaCl 0.9% 6 hours | 4.71 | 1.741 | 0.922 | |||
ACTH4-10 3 hours | 14.64 | 2.893 | <0.001* | |||
ACTH4-10 6 hours | 11.46 | 1.350 | <0.001* | |||
NaCl 0.9% 3 hour | 6.86 | 1.848 | NaCl 0.9% 6 hours | 4.71 | 1.741 | 0.268 |
ACTH4-10 3 hours | 14.64 | 2.893 | <0.001* | |||
ACTH4-10 6 hours | 11.46 | 1.350 | <0.001* | |||
NaCl 0.9% 6 hour | 4.71 | 1.741 | ACTH4-10 3 hours | 14.64 | 2.893 | <0.001* |
ACTH4-10 6 hours | 11.46 | 1.350 | <0.001* | |||
ACTH4-10 3 hour | 14.64 | 2.893 | ACTH4-10 6 hours | 11.46 | 1.350 | 0.036* |
Group | Mean | Standard deviation | Group | Mean | Standard deviation | p |
---|---|---|---|---|---|---|
Control | 3.86 | 1.682 | NaCl 0.9% 3 hours | 7.86 | 2.445 | 0.023* |
NaCl 0.9% 6 hours | 6.25 | 2.046 | 0.322 | |||
ACTH4-10 3 hours | 13.36 | 1.676 | <0.001* | |||
ACTH4-10 6 hours | 11.57 | 3.313 | <0.001* | |||
NaCl 0.9% 3 hour | 7.86 | 2.445 | NaCl 0.9% 6 hours | 6.25 | 2.046 | 0.694 |
ACTH4-10 3 hours | 13.36 | 1.676 | 0.001* | |||
ACTH4-10 6 hours | 11.57 | 3.313 | 0.040* | |||
NaCl 0.9% 6 hour | 6.25 | 2.046 | ACTH4-10 3 hours | 13.36 | 1.676 | <0.001* |
ACTH4-10 6 hours | 11.57 | 3.313 | 0.001* | |||
ACTH4-10 3 hour | 13.36 | 1.676 | ACTH4-10 6 hours | 11.57 | 3.313 | 0.605 |
Group | Mean | Standard deviation | Group | Mean | Standard deviation | p |
---|---|---|---|---|---|---|
Control | 5.75 | 2.20 | NaCl 0.9% 3 hours | 7.32 | 2.26 | 0.600 |
NaCl 0.9% 6 hours | 5.29 | 2.16 | 0.993 | |||
ACTH4-10 3 hours | 9.36 | 1.98 | 0.018* | |||
ACTH4-10 6 hours | 9.21 | 1.37 | 0.025* | |||
NaCl 0.9% 3 hour | 7.32 | 2.26 | NaCl 0.9% 6 hours | 5.29 | 2.16 | 0.349 |
ACTH4-10 3 hours | 9.36 | 1.98 | 0.349 | |||
ACTH4-10 6 hours | 9.21 | 1.37 | 0.421 | |||
NaCl 0.9% 6 hour | 5.29 | 2.16 | ACTH4-10 3 hours | 9.36 | 1.98 | 0.006* |
ACTH4-10 6 hours | 9.21 | 1.37 | 0.009* | |||
ACTH4-10 3 hour | 9.36 | 1.98 | ACTH4-10 6 hours | 9.21 | 1.37 | 1.000 |
Group | Mean | Standard deviation | Group | Mean | Standard deviation | p |
---|---|---|---|---|---|---|
Control | 5.36 | 1.587 | NaCl 0.9% 3 hours | 7.07 | 2.344 | 0.607 |
NaCl 0.9% 6 hours | 5.71 | 1.629 | 0.998 | |||
ACTH4-10 3 hours | 13.25 | 3.086 | <0.001* | |||
ACTH4-10 6 hours | 9.54 | 2.138 | 0.012 | |||
NaCl 0.9% 3 hour | 7.07 | 2.344 | NaCl 0.9% 6 hours | 5.71 | 1.629 | 0.784 |
ACTH4-10 3 hours | 13.25 | 3.086 | <0.001* | |||
ACTH4-10 6 hours | 9.54 | 2.138 | 0.258 | |||
NaCl 0.9% 6 hour | 5.71 | 1.629 | ACTH4-10 3 hours | 13.25 | 3.086 | <0.001* |
ACTH4-10 6 hours | 9.54 | 2.138 | 0.024* | |||
ACTH4-10 3 hour | 13.25 | 3.086 | ACTH4-10 6 hours | 9.54 | 2.138 | 0.030* |
Group | Mean | Standard deviation | Group | Mean | Standard deviation | p |
---|---|---|---|---|---|---|
Control | 4.50 | 1.893 | NaCl 0.9% 3 hours | 5.79 | 1.410 | 0.816 |
NaCl 0.9% 6 hours | 5.68 | 1.718 | 0.858 | |||
ACTH4-10 3 hours | 10.18 | 3.570 | <0.001 | |||
ACTH4-10 6 hours | 9.00 | 1.893 | 0.006* | |||
NaCl 0.9% 3 hour | 5.79 | 1.410 | NaCl 0.9% 6 hours | 5.68 | 1.718 | 1.000 |
ACTH4-10 3 hours | 10.18 | 3.570 | 0.007* | |||
ACTH4-10 6 hours | 9.00 | 1.893 | 0.078 | |||
NaCl 0.9% 6 hour | 5.68 | 1.718 | ACTH4-10 3 hours | 10.18 | 3.570 | 0.006* |
ACTH4-10 6 hours | 9.00 | 1.893 | 0.064 | |||
ACTH4-10 3 hour | 10.18 | 3.570 | ACTH4-10 6 hours | 9.00 | 1.893 | 0.858 |
Mean levels of IL4, IL-10 and IL-13 were higher in the mild SCI models group that was given ACTH4-10Pro8-Gly9-Pro10 for both three- and six-hour termination groups, compared with placebo. IL-14 levels in models given ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 10.39 and 8.05 respectively, and 6.29 and 5.61 respectively in the placebo group. IL-10 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 14.64 and 11.46 respectively, while in the placebo group they were 6.86 and 4.71 respectively. IL-13 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 13.36 and 11.57 respectively, and 7.86 and 6.25 respectively in the placebo group. Post hoc analysis with Tukey test showed significant differences in IL-4, IL-10 and IL-13 at three hours, and in IL-10 and IL-13 at six hours.
The results from severe SCI models that were given ACTH4-10Pro8-Gly9-Pro10 also showed higher mean IL-4, IL-10 and IL-13 levels compared with placebos in the three-hour and six-hour groups. IL-4 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 9.36 and 9.21 respectively, and 7.82 and 5.29 respectively in the placebo. IL-10 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hourswas 13.25 and 9.54 respectively, while in placebos they were 7.07 and 5.71, respectively. IL-13 levels in models administered ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 10.18 and 9.00 respectively, while in placebo they were 5.79 and 5.68 respectively. Post hoc analysis with Tukey test showed significant differences in IL-10 and IL-13 levels at three hours, and in IL-4 and IL-10 at six hours. Overall, level of anti-inflammatory cytokines were higher in each treatment group compared with placebo; the levels were significantly higher in models with mild SCI and terminated three hours after injury.
Inflammation following the primary spinal cord injury is known to cause further spinal cord damage, resulting in apoptosis of oligodendrocyte, demyelination and degradation of axons, and neuronal cell death. Many attempts were made to reduce this deleterious effect caused by inflammation after initial injury occurrs.14
Neuroinflammation following the primary injury is predominantly regulated by the balance of macrophage activation.15 In order to regulate this inflammation cascade, macrophages play a key role by releasing pro- or anti-inflammatory cytokine. Studies in SCI models have shown that some pro-inflammatory cytokines like TNF-α, IL-1, and IL-6 are found upregulated within an hour after injury, leading to further inflammatory response causing neuronal apoptosis.16 In contrast, anti-inflammatory cytokines that are capable of altering macrophage activity, such as IL-4, IL-1316–19 and IL-10 which can directly inhibiting other pro-inflammatory cytokines, are generally present at low levels after SCI.20,21
We realize sex hormone like estrogen and progesterone have some immunosuppressive profile in SCI22; to minimize this potentially confounding factor that might bias the outcome we only used male Sprague Dawley rats in this study. Our study found significantly higher IL-4, IL-10 and IL-13 levels in the mild SCI group that was terminated after three hours, and higher IL-10, IL-13 levels in the six-hour termination group that was given ACTH4-10. In the severe SCI group that were given ACTH4-10, we found higher IL-10, IL-13 levels in the group that was terminated after three hours, and higher IL-4 and IL-10 levels after six hours.
Compared with mild SCI, in the severe SCI group inflammation was more pronounced and abundant in pro-inflammatory cytokines. These pro-inflammatory cytokines in turn could suppress the release of anti-inflammatory cytokines. In addition, inflammation that occurs in SCI rat models is known to begin one hour after injury and reach its peak at six hours after injury.23 This may explain our finding that in the group with severe SCI and termination six hours after injury, anti-inflammatory cytokine expression ratio between the ACTH4-10Pro8- Gly9-Pro10 and placebo groups was not as high as in the mild SCI and three-hour group.
ACTH4-10Pro8-Gly9-Pro10 is an analogue of adrenocorticotropic hormone and is created from a fragment of ACTH(4–7) combined with C-terminal tripeptide Pro-Gly-Pro, which acts as a neuroprotective compound.24 Similar to its analogue, ACTH4-10Pro8-Gly9-Pro10 is said to bind at the melanocortin receptor promoting anti-inflammatory and neuroprotective effects.25 Activated melanocortin receptors could supress pro-inflammatory cytokine release and promote the anti-inflammatory cytokine release. Together, this condition could supress inflammation.26
Methylprednisolone sodium succinate (MP) became the most discussed treatment in the last three to four decades for reducing the deleterious effect caused by inflammation after initial injury occurs. The first study that was conducted in the early 1980s showed a promising potential neuroprotective effect of MP in reducing inflammation after acute SCI in a preclinical setting. This study has led many clinicians to do more extensive research (NASCIS I and II).27,28 This large-scale randomized control trial showed that there was a statistical improvement in neurological outcomes in the treatment group compared with the placebo if MP was administered within less than eight hours after initial injury.28,29 However, with an average increase of just five points in the American Spinal Injury Association (ASIA) impairment score compared with the placebo, this was said to not be clinically significant in the overall quality of life of the patient. Moreover, along with the limited overall improvement, a high dose of MP came with several complications, such as increased rate of infection along with gastrointestinal haemorrhages.30,31 Considering the limited benefit and potential morbidity or even life-threatening complications, in 2013 the American Association of Neurological Surgeon (AANS) ruled out MP administration from the current recommendations for managing patients with SCI.32,33
Our finding showing increased levels of anti-inflammatory cytokines in the treatment group complements previous studies that revealed ACTH4-10Pro8-Gly9-Pro10 could decrease pro-inflammatory cytokines in SCI rats model.34,35 Those studies might provide a fundamental basis showing ACTH4-10Pro8- Gly9-Pro10 could reduce inflammation and potentially prevent secondary injury in SCI. To date, ACTH4-10Pro8- Gly9-Pro10 has been used as a neuroprotective agent for stroke and Alzheimer patients with no report of serious complications. It has also been given through the intranasal route and has a rapid onset within minute, allowing this drug to be given early on after the initial injury. Finally, we see potential benefits from ACTH4-10Pro8- Gly9-Pro10 to reduce inflammation and its deleterious effect on secondary injury after SCI.
Administration of ACTH4-10Pro8-Gly9-Pro10 can increase anti-inflammatory cytokine levels in Sprague Dawley rat models with mild and severe SCI. Rats with mild compression that were terminate after three hours showed an increase in IL-4, IL-10 and IL-13; after six hours, only IL-10 and IL-13 were increased. Rats with severe compression that were terminate after three hours showed an increase in IL-10 and IL-13; after six hours, only IL-4, IL-10 were increased. Further studies are needed to determine the optimal dose and functional outcome in rats with SCI.
DRYAD: Effects of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury model (Sprague Dawley rats), https://doi.org/10.5281/zenodo.7446188. 36
Zenodo: Effects of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury model (Sprague Dawley rats), https://doi.org/10.5281/zenodo.7568360. 37
Zenodo: ARRIVE checklist for “Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats)”, https://doi.org/10.5281/zenodo.7568360. 37
Data are available under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Neurology, Genetic
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |
---|---|
1 | |
Version 1 20 Feb 23 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)